Aurinia Pharmaceuticals Inc (AUPH) — closed signal from July 8, 2026
Near target Published before the outcome was known, scored automatically when the window closed on October 6, 2026 — -5.1% at the close.
Predicted vs. what happened
What happened
Came within reach: 84% of the predicted growth at its peak, just short of the target.
The thesis — published July 8, 2026
Aurinia is a small healthcare recovery idea tied to sales of LUPKYNIS, other pipeline hopes, and investor attention. Recent press caused a price uptick and a higher outside valuation, but the company's official upside looks limited and trading activity is light. The stock may try to rebound over 0-3 months, yet heavy short positions and negative price momentum raise the chance of further swings.
Primary drivers
- LUPKYNIS sales remain the main commercial growth driver
- Pipeline progress and activist attention create extra upside possibilities
- A solid balance sheet reduces small-company financial risk
- Low trading volume and many short positions make price swings larger
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.